Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Collegium Pharmaceutical Inc Market Cap
The Collegium Pharmaceutical Inc (COLL) share price is expected to increase by 40.97% over the next year. This is based on calculating the average 12-month share price estimate provided by 5 stock analysts who have covered COLL. Price targets range from $37 at the low end to $50 at the high end. The current analyst consensus for COLL is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
COLL is a stock in Healthcare which has been forecasted to be worth $42.25 as an average. On the higher end, the forecast price is $50 USD by Oren Livnat from HC Wainwright & Co. and on the lower end COLL is forecasted to be $37 by Gregg Gilbert from Truist Securities.
These are the latest 20 analyst ratings of COLL.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| David Amsellem Piper Sandler | Neutral | $37 | Reiterates | Oct 11, 2024 |
| Oren Livnat HC Wainwright & Co. | Buy | $50 | Maintains | Sep 5, 2024 |
| Les Sulewski Truist Securities | Buy | $42 | Maintains | Aug 9, 2024 |
| Serge Belanger Needham | Hold | Reiterates | Aug 9, 2024 | |
| David Amsellem Piper Sandler | Neutral | $37 | Reiterates | Aug 9, 2024 |
| Oren Livnat HC Wainwright & Co. | Buy | $47 | Upgrade | Jul 30, 2024 |
| Serge Belanger Needham | Hold | Reiterates | Jul 30, 2024 | |
| Glen Santangelo Jefferies | Buy | $44 | Upgrade | Jun 7, 2024 |
| Serge Belanger Needham | Hold | Downgrade | May 10, 2024 | |
| David Amsellem Piper Sandler | Neutral | $39 | Downgrade | May 10, 2024 |
| Serge Belanger Needham | Buy | $40 | Reiterates | Apr 11, 2024 |
| Les Sulewski Truist Securities | Buy | $40 | Maintains | Feb 26, 2024 |
| David Amsellem Piper Sandler | Overweight | $39 | Reiterates | Feb 23, 2024 |
| Serge Belanger Needham | Buy | $40 | Reiterates | Feb 2, 2024 |
| Glen Santangelo Jefferies | Hold | $37 | Downgrade | Jan 4, 2024 |
| Gregg Gilbert Truist Securities | Buy | $37 | Maintains | Jan 4, 2024 |
| Serge Belanger Needham | Buy | $40 | Maintains | Jan 4, 2024 |
| Serge Belanger Needham | Buy | $36 | Maintains | Aug 25, 2023 |
| Oren Livnat HC Wainwright & Co. | Neutral | Reiterates | Aug 4, 2023 | |
| Serge Belanger Needham | Buy | $35 | Reiterates | Aug 4, 2023 |
When did it IPO
2015
Staff Count
197
Country
United States
Sector/Industry
Healthcare/Drug Manufacturers - Specialty & Generic
CEO
Mr. Vikram Karnani
Market Cap
$966.5M
In 2023, COLL generated $566.8M in revenue, which was a increase of 22.17% from the previous year. This can be seen as a signal that COLL's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 26 Nov 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Collegium Pharmaceutical's Q3 2024 revenue grew 17% YoY, driven by its pain management products. The acquisition of Jornay PM targets the expanding ADHD market, projected at $30.6 billion by 2032.
Why It Matters - Collegium's strong revenue growth and market leadership in pain management, combined with the ADHD market expansion, indicate robust future potential and operational efficiency, positively influencing investor confidence.
Thu, 14 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Knight Therapeutics Inc. (TSX: GUD) has received Health Canada approval for JORNAY PM™, an extended-release ADHD treatment for children, enhancing its product portfolio.
Why It Matters - Knight Therapeutics' approval of JORNAY PM™ enhances its product portfolio, potentially boosting revenue and market share in the ADHD treatment segment, which can positively influence stock performance.
Wed, 13 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Zacks emphasizes its Rank system, focusing on earnings estimates and revisions to identify strong stock picks, while also monitoring value, growth, and momentum trends.
Why It Matters - Zacks' emphasis on earnings estimates and revisions signals potential stock performance, guiding investors to identify promising opportunities in value, growth, and momentum.
Fri, 08 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Collegium Pharmaceutical (NASDAQ: COLL) will hold its Q3 2024 earnings conference call on November 7, 2024, at 4:30 PM ET, featuring key executives and analysts.
Why It Matters - Collegium Pharmaceutical's Q3 earnings call indicates upcoming financial performance insights, impacting stock valuation and investor sentiment. Key executives' participation suggests strategic updates.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Q3'24 net revenue reached $159.3 million, a 17% increase YoY, fueled by record revenues from Belbuca® at $53.2 million and Xtampza® ER at $49.5 million.
Why It Matters - Record Q3'24 net revenue indicates strong company performance and growth potential, driven by successful products, which can positively influence stock prices and investor confidence.
Thu, 07 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Collegium Pharmaceutical (COLL) reported Q3 earnings of $1.61 per share, below the Zacks Consensus Estimate of $1.66, but up from $1.34 per share a year earlier.
Why It Matters - Collegium Pharmaceutical's earnings miss could signal potential challenges in growth or market demand, impacting investor confidence and stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
